Any current/future new fundraising through debt or equity?

No current plans for growth capex this year or next, so no immediate debt needed for expansion (Manish Poddar). No acquisitions lined up presently, but an approved credit line of €40 million is available until August 2028 for potential future acquisitions (Tarak Patel). The company has refinanced existing debt, extending maturity from 2026 to 2028, maintaining good banking relationships in India to support future deals (Tarak Patel, Manish Poddar). The extension and increase in LC facility and pledge modification are part of refinancing and not indicative of new borrowing for growth currently.

Any current/future capex/capital investment/strategic investment?

No growth capex is planned for the current financial year or the next financial year. Maintenance capex is expected to be minimal, around 2%-2.5%, likely lower for this year. The company does not anticipate any significant capacity expansion in the near term (next 1-2 years). There is an approved additional borrowing line of €40 million available for potential acquisitions up to August 2028, though no acquisitions are currently lined up. The management remains open to strategic acquisitions for diversification but has no immediate plans to deploy this facility. Focus is on internal c

Future growth expectations in sales/revenue/volumes?

The company expects 5% to 10% growth in revenue and profitability for FY25, describing the year as one of consolidation and internal focus. Order intake is currently strong, with the highest in eight quarters, and backlog poised for execution through the year. Long-term aspiration includes quarter-on-quarter growth with a target around 25%, though short-term quarters may not always align with this. Diversification away from the chemical and pharma sectors is planned to reduce dependency and tap into faster-growing industries. Systems business and industrial mixing are growth areas, con

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects modest revenue and profitability growth of around 5%-10% for FY25 as the market recovers from a slowdown, especially in chemical and agrochemical sectors. Margins are expected to remain stable at around 13%-13.5% EBITDA, with potential slight improvement if volumes pick up. Capacity utilization improvements could add 2%-3% margin enhancement over time. Cost efficiency programs underway in India manufacturing aim to improve margins over 9-12 months. Diversification away from glass-lined business toward Systems, Mixing, Heavy Engineering, and Services may enhance earnings sta

Current/ Expected Orderbook/ Pending Orders?

Current executable order backlog stands at approximately Rs. 1,777 crores. Rs. 785 crores worth of orders have already been executed in Q1 FY25. Order intake in Q1 was Rs. 882 crores, the highest in the last eight quarters. Strong order intake driven by Heavy Engineering, Mixing, and Systems businesses. Order backlog is up 5% compared to previous periods. Majority of the backlog and new orders expected to be executed within the current calendar year. International orders may have slightly longer delivery timelines, potentially leading to some spillover beyond this year. The compa

IN US

Sale is live|00:00:00left today

GMM Pfaudler LtdQ2 FY24Industrial Manufacturing

GMM Pfaudler Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹793P/E: 36.0Market Cap: ₹4.0K CrSector: Industrial Manufacturing

Management growth scorecard

Revenue

Category 4

Margin

Category 2

Fundraise

Order

Yes

Capex

1 of 5 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→The company expects 5% to 10% growth in revenue and profitability for FY25, describing the year as one of consolidation and internal focus.
→Order intake is currently strong, with the highest in eight quarters, and backlog poised for execution through the year.
→Long-term aspiration includes quarter-on-quarter growth with a target around 25%, though short-term quarters may not always align with this.
→Diversification away from the chemical and pharma sectors is planned to reduce dependency and tap into faster-growing industries.
→Systems business and industrial mixing are growth areas, contributing significantly to recent revenues.
→Heavy engineering and non-glass lined businesses are expected to make up for slowdowns in glass-lined segments.
→Management aims for stable or marginally improved EBITDA margins with volume growth supporting margin expansion.
→There are no plans for major growth capex, indicating focus on optimizing existing capacities.

Margin guidance

Category 2

→The company expects modest revenue and profitability growth of around 5%-10% for FY25 as the market recovers from a slowdown, especially in chemical and agrochemical sectors.
→Margins are expected to remain stable at around 13%-13.5% EBITDA, with potential slight improvement if volumes pick up.
→Capacity utilization improvements could add 2%-3% margin enhancement over time.
→Cost efficiency programs underway in India manufacturing aim to improve margins over 9-12 months.
→Diversification away from glass-lined business toward Systems, Mixing, Heavy Engineering, and Services may enhance earnings stability and growth.
→No major growth capex planned for next 1-2 years; focus is on internal optimization and backlog execution.
→Management will release a detailed 3-year strategic plan soon, outlining growth and de-risking strategies.
→Industrial mixing and Systems businesses expected to grow gradually and contribute positively over the medium term.

3 more insights locked — sign up free to unlock

Fundraise plans

→No current plans for growth capex this year or next, so no immediate debt needed for expansion (Manish Poddar).
→No acquisitions lined up presently, but an approved credit line of €40 million is available until August 2028 for potential future acquisitions (Tarak Patel).
→The company has refinanced existing debt, extending maturity from 2026 to 2028, maintaining good banking relationships in India to support future deals (Tarak Patel, Manish Poddar).
→The extension and increase in LC facility and pledge modification are part of refinancing and not indicative of new borrowing for growth currently.
→Management remains open to acquisition opportunities as they arise but no active fundraise through equity or debt reported at this time (Tarak Patel).

Order book

Yes

→Current executable order backlog stands at approximately Rs. 1,777 crores.
→Rs. 785 crores worth of orders have already been executed in Q1 FY25.
→Order intake in Q1 was Rs. 882 crores, the highest in the last eight quarters.
→Strong order intake driven by Heavy Engineering, Mixing, and Systems businesses.
→Order backlog is up 5% compared to previous periods.
→Majority of the backlog and new orders expected to be executed within the current calendar year.
→International orders may have slightly longer delivery timelines, potentially leading to some spillover beyond this year.
→The company expects order intake momentum to continue in Q2 and Q3, supporting revenue growth forecasts.

Capex plans

→No growth capex is planned for the current financial year or the next financial year.
→Maintenance capex is expected to be minimal, around 2%-2.5%, likely lower for this year.
→The company does not anticipate any significant capacity expansion in the near term (next 1-2 years).
→There is an approved additional borrowing line of €40 million available for potential acquisitions up to August 2028, though no acquisitions are currently lined up.
→The management remains open to strategic acquisitions for diversification but has no immediate plans to deploy this facility.
→Focus is on internal cost-efficiency programs, capacity utilization improvements, and diversification rather than new capital investments.

How does GMM Pfaudler Ltd rank vs peers in Industrial Manufacturing?

Pro feature

1GMM Pfaudler Ltd

Rev 4Mar 2

See full Industrial Manufacturing sector rankings

Want more stocks like GMM Pfaudler Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio